Transcatheter Pulmonary Valve Replacement in Native RVOT

31 Pages·2016·4.08 MB·English

Jamil Aboulhosn, M.D.
Streisand/American Heart Association Chair in Cardiology
Director, Ahmanson/UCLA Adult Congenital Heart Disease
Center
Advisory Board and Research Grant Funding-

Actelion Pharmaceuticals
Research Grant Funding- St Jude, United

Therapeutics, Heartware, Medtronic,
Edwards Lifesciences
Proctor- Edwards Lifesciences

Disclosure of ABIM Service: Jamil Aboulhosn, MD

 I am a current member of the Cardiology Board Adult Congenital
Heart Disease Exam Committee.

 To protect the integrity of certification, ABIM enforces strict
confidentiality and ownership of exam content.

 As a current member of the Cardiology Board Adult Congenital
Heart Disease Exam Committee, I agree to keep exam information
confidential.

 As is true for any ABIM candidate who has taken an exam
for certification, I have signed the Pledge of Honesty in which
I have agreed to keep ABIM exam content confidential.

No exam questions will be disclosed in my presentation.
Usually after surgical

treatment of PS or
tetralogy of Fallot
Well tolerated for 10-20

years
Progressive RVE, RAE,

atrial and ventricular
arrhythmias, right heart
failure, progressive TR
Eventual multi-organ

failure
MELODY® Transcatheter
Pulmonary Valve is intended to:
• 18mm Modified Contegra Bovine
Jugular Vein Valve
• Platinum Iridium Frame
▶ 28mm length
▶ Crimped down to 6mm
▶ Re-expanded 18mm up to 24mm

• BIG RVOTs…..
• BIG Valves…..
• BIG delivery
systems
• Sapien XT,S3
• Stiffness
• Obstacles
• TV
• RVOT
• Branch PAs
8
9
10